39 related articles for article (PubMed ID: 17875772)
21. Multidrug Efflux Pumps Attenuate the Effect of MGMT Inhibitors.
Tomaszowski KH; Schirrmacher R; Kaina B
Mol Pharm; 2015 Nov; 12(11):3924-34. PubMed ID: 26379107
[TBL] [Abstract][Full Text] [Related]
22. MGMT repletion after treatment of glioblastoma cells with temozolomide and O6-benzylguanine implicates NFκB and mutant p53.
Vlachostergios PJ; Hatzidaki E; Papandreou CN
Neurol Res; 2013 Oct; 35(8):879-82. PubMed ID: 23561593
[TBL] [Abstract][Full Text] [Related]
23. Acridine-O
Franco Pinto J; Fillion A; Duchambon P; Bombard S; Granzhan A
Eur J Med Chem; 2022 Jan; 227():113909. PubMed ID: 34731767
[TBL] [Abstract][Full Text] [Related]
24. Sensitization of pancreatic tumor xenografts to carmustine and temozolomide by inactivation of their O6-Methylguanine-DNA methyltransferase with O6-benzylguanine or O6-benzyl-2'-deoxyguanosine.
Kokkinakis DM; Ahmed MM; Chendil D; Moschel RC; Pegg AE
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3801-7. PubMed ID: 14506174
[TBL] [Abstract][Full Text] [Related]
25. Modulating MGMT expression through interfering with cell signaling pathways.
Bai P; Fan T; Wang X; Zhao L; Zhong R; Sun G
Biochem Pharmacol; 2023 Sep; 215():115726. PubMed ID: 37524206
[TBL] [Abstract][Full Text] [Related]
26. Pituitary carcinomas and aggressive pituitary tumours: merits and pitfalls of temozolomide treatment.
Raverot G; Castinetti F; Jouanneau E; Morange I; Figarella-Branger D; Dufour H; Trouillas J; Brue T
Clin Endocrinol (Oxf); 2012 Jun; 76(6):769-75. PubMed ID: 22404748
[TBL] [Abstract][Full Text] [Related]
27. Circumventing melanoma chemoresistance by targeting DNA repair.
Mocellin S; Bertazza L; Benna C; Pilati P
Curr Med Chem; 2012; 19(23):3893-9. PubMed ID: 22788765
[TBL] [Abstract][Full Text] [Related]
28. Nitrosoureas: molecular pharmacology/ translational research.
D'Incalci M
Tumori; 2007; 93(3):suppl 17-21. PubMed ID: 17679484
[No Abstract] [Full Text] [Related]
29. Targeting methylguanine-DNA methyltransferase in the treatment of neuroblastoma.
Wagner LM; McLendon RE; Yoon KJ; Weiss BD; Billups CA; Danks MK
Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5418-25. PubMed ID: 17875772
[TBL] [Abstract][Full Text] [Related]
30. A novel approach to overcome temozolomide resistance in glioma and melanoma: Inactivation of MGMT by gene therapy.
Jiang G; Wei ZP; Pei DS; Xin Y; Liu YQ; Zheng JN
Biochem Biophys Res Commun; 2011 Mar; 406(3):311-4. PubMed ID: 21329652
[TBL] [Abstract][Full Text] [Related]
31. The role of temozolomide in the treatment of aggressive pituitary tumors.
Liu JK; Patel J; Eloy JA
J Clin Neurosci; 2015 Jun; 22(6):923-9. PubMed ID: 25772801
[TBL] [Abstract][Full Text] [Related]
32. Treatment of pituitary neoplasms with temozolomide: a review.
Syro LV; Ortiz LD; Scheithauer BW; Lloyd R; Lau Q; Gonzalez R; Uribe H; Cusimano M; Kovacs K; Horvath E
Cancer; 2011 Feb; 117(3):454-62. PubMed ID: 20845485
[TBL] [Abstract][Full Text] [Related]
33. Triazene compounds: mechanism of action and related DNA repair systems.
Marchesi F; Turriziani M; Tortorelli G; Avvisati G; Torino F; De Vecchis L
Pharmacol Res; 2007 Oct; 56(4):275-87. PubMed ID: 17897837
[TBL] [Abstract][Full Text] [Related]
34. Critical appraisal of MGMT in digestive NET treated with alkylating agents.
de Mestier L; Couvelard A; Blazevic A; Hentic O; de Herder WW; Rebours V; Paradis V; Ruszniewski P; Hofland LJ; Cros J
Endocr Relat Cancer; 2020 Oct; 27(10):R391-R405. PubMed ID: 32698158
[TBL] [Abstract][Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [New Search]
